D-penicillamine in the neonatal period: Possible beneficial effects on the lethality of HIV infection due to vertical transmission

György Balla, Lajos Lakatos, István Pataki, Zsuzsanna Vekerdy-Nagy, György Oroszlán

Research output: Contribution to journalArticle

Abstract

D-penicillamine (DPA) was first recognized as a potential benefit for neonatal hyperbilirubinemia (NHBI). During this time there was a remarkedly low incidence of retinopathy of prematurity (ROP) in the infants treated with DPA. Later, our studies were replicated in other institutes in Hungary, Poland, the U.S. A., India and Mexico. It is important to note that there was no intolerance or short- or long-term toxicity of the medication, in spite of the fact that in the newborn period DPA was used 10-20 times higher doses than those in adult. On the basis of an American research work concerning the beneficial effects of DPA-therapy in adult AIDS-patients (although in these cases there were many unpleasant, adverse effects), it would be reasonable to treat neonatal HIV-positivity due to vertical transmission with short-term DPA therapy (300 - 400 mg/kg/bw/day for 5-7 days). Therefore, we have a moral obligation to help the fight against HIV with this inexpensive (~ 30 USD/baby) drug in the neonatal period.

Original languageEnglish
Article number07
Pages (from-to)30-42
Number of pages13
JournalInternational Journal of Pharmaceutical Sciences Review and Research
Volume33
Issue number2
Publication statusPublished - Jul 1 2015

Keywords

  • D-penicillamine
  • HIV/AIDS therapy
  • Neonatal hyperbilirubinemia
  • Retinopathy of prematurity

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'D-penicillamine in the neonatal period: Possible beneficial effects on the lethality of HIV infection due to vertical transmission'. Together they form a unique fingerprint.

  • Cite this